Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18211368 | 0.83 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL27638544 | 0.81 | PYGL (0.32) | CA14PYGL | |
| SCHEMBL26109970 | 0.79 | HDAC6 (0.37) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL29126662 | 0.79 | HDAC6 (0.37) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL503444 | 0.78 | CA14 (0.53) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL12928688 | 0.78 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL30420929 | 0.78 | CA14 (0.41) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL25338216 | 0.78 | CYP4F2 (0.38) | — | |
| SCHEMBL14889943 | 0.78 | CHRNB2 (0.39) | — | |
| SCHEMBL745378 | 0.77 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9883674-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170258089-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9686991-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-0581167-B1 | Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria | KYORIN SEIYAKU KK (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5439919-A | Treatment of urinary incontinence | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| EP-0581167-A1 | Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258089-A1 | ANTIPARASITIC COMPOUNDS | ACHE, DDT, NISCH | CA14 4473/4885SSTR4 3022/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.